GLP-1 + Birth Control: Tirzepatide Pill Warning + Wegovy / Ozempic

Only one GLP-1/GIP class member carries a labelled oral-contraceptive warning: tirzepatide. The Zepbound and Mounjaro FDA labels report a 55–66% reduction in oral-contraceptive peak concentration (C_max) and a 20–23% reduction in total drug exposure (AUC) at a single 5 mg tirzepatide dose^[1][2]. Semaglutide(Ozempic, Wegovy, Rybelsus) does not — the Ozempic label states that “semaglutide did not affect the absorption of orally administered medications to any clinically relevant degree”^[4]. Liraglutide(Saxenda) carries no oral-contraceptive warning either^[5]. This article walks through the labels verbatim, the mechanism (it is gastric emptying, not metabolism), and the four practical workarounds: switch to a non-oral form, add a barrier for 4 weeks after each tirzepatide dose escalation, switch to semaglutide if oral contraception is non-negotiable, or use an IUD that bypasses the interaction entirely.

The honest summary

• Tirzepatide is the only labelled offender. The Zepbound and Mounjaro prescribing information section 7 specifies oral contraceptives “may be less effective” with tirzepatide, citing a single-dose interaction study showing 55–66% C_max and 20–23% AUC reductions at tirzepatide 5 mg^[1][2].
• The fix is mechanical, not metabolic. The interaction is driven by slowed gastric emptying, which delays and partially abolishes intestinal absorption of the oral pill. Anything that bypasses oral absorption — transdermal patch, vaginal ring, depot injection, implant, IUD — is unaffected.
• Switch or barrier for 4 weeks after initiation and each dose increase. Tirzepatide titrates 2.5 to 5 to 7.5 to 10 to 12.5 to 15 mg in 4-week steps; each step re-induces the gastric-emptying delay, so 4 weeks of barrier coverage after each step is the conservative read of the label.
• Semaglutide is the carve-out. The Ozempic and Wegovy labels include no oral-contraceptive warning; the Ozempic pharmacokinetics section explicitly clears oral medications^[3][4]. Saxenda (liraglutide) is also clear^[5].
• Pregnancy washout still applies. Whatever contraceptive you use, the 2-month pre-conception discontinuation guidance for all GLP-1s remains in force (see linked article below).

The Zepbound and Mounjaro label, verbatim

Section 7.1 of the Zepbound prescribing information (DailyMed SetID 487cd7e7^[1]) and the matching section of the Mounjaro label (SetID d2d7da5d^[2]) read, in substance:

“Oral hormonal contraceptives may be less effective when co-administered with [tirzepatide]. The effect of a single oral dose of a combined oral contraceptive on C_max and AUC was decreased by 59% and 20%, respectively… Patients using oral hormonal contraceptives should be advised to switch to a non-oral contraceptive method, or add a barrier method of contraception, for 4 weeks after initiation and for 4 weeks after each dose escalation with [tirzepatide].”

The single-dose interaction study cited in the label tested an ethinyl estradiol / norgestimate combined oral contraceptive coadministered with a single 5 mg dose of tirzepatide. Across the two active components, peak concentration (C_max) fell 55% (norgestimate) and 66% (ethinyl estradiol), and AUC fell 20–23%. The label generalizes the finding to all oral combined and progestin-only contraceptives because the mechanism — delayed gastric emptying impairing oral absorption — is non-specific.

The Wegovy and Ozempic label, verbatim

The Ozempic label (DailyMed SetID adec4fd2^[4]) section 12.3 (Pharmacokinetics, Drug Interaction Studies) states:

“Semaglutide delays gastric emptying and thereby has the potential to impact the absorption of concomitantly administered oral medications. In trials evaluating coadministration of semaglutide with orally administered medications, semaglutide did not affect the absorption of the tested oral medications to any clinically relevant degree.”

The Wegovy label (SetID ee06186f^[3]) mirrors that language. Pharmacokinetic studies of semaglutide coadministered with an ethinyl estradiol / levonorgestrel combined oral contraceptive found no clinically meaningful change in C_max or AUC. The semaglutide labels therefore do not require a contraceptive switch or barrier method.

Why the divergence between tirzepatide and semaglutide if the mechanism — delayed gastric emptying — is shared? The most parsimonious explanation is that tirzepatide's dual GIP/GLP-1 agonism produces a deeper and longer-lasting gastric-emptying delay, particularly at the high doses needed for the obesity indication. Whether the difference is clinically meaningful at every dose level has not been directly tested, but the labels are what they are: tirzepatide carries the warning, semaglutide does not.

Saxenda and the orforglipron picture

Saxenda (liraglutide, SetID 3946d389^[5]) carries no oral-contraceptive warning. The liraglutide pharmacokinetic program tested coadministration with ethinyl estradiol / levonorgestrel and found no clinically relevant change.

Orforglipron, Eli Lilly's daily oral small-molecule GLP-1 receptor agonist (brand candidate Foundayo), reported primary obesity efficacy in ATTAIN-1 (Wharton 2025 NEJM^[6]). The submitted prescribing information at time of this review does not include a labelled oral-contraceptive warning, but the program is recent and the label may evolve. We will update this article when the FDA labelling document is published in DailyMed.

The mechanism: gastric emptying, not metabolism

Oral combined and progestin-only pills depend on intact upper-gastrointestinal absorption: the tablet dissolves in the stomach, the active hormones are absorbed across the duodenum and proximal jejunum, and steady-state hormone levels are maintained by daily redosing. GLP-1 receptor agonism delays gastric emptying as a class effect, with the magnitude varying by molecule and dose. When emptying is delayed enough, the tablet sits in the stomach past its absorption window, dissolves into a stomach that is recirculating contents rather than passing them onward, and peak hormone concentration falls.

Importantly, this is not a metabolic interaction at the level of CYP450 enzymes. There is no induction or inhibition of contraceptive metabolism. Anything that bypasses oral absorption is therefore unaffected:

• Transdermal patches (Xulane, Twirla) deliver hormone directly into the systemic circulation through skin. No gastric emptying involved.
• Vaginal rings (NuvaRing, Annovera) release hormone locally with systemic absorption through vaginal mucosa.
• Depot injections (Depo-Provera, every 12 weeks) bypass the gut entirely.
• Subdermal implants (Nexplanon, etonogestrel, 3-year duration) release hormone directly into systemic circulation.
• Intrauterine devices (Mirena, Kyleena, Skyla, Liletta progestin IUDs; Paragard copper) act locally in the uterus — the systemic levonorgestrel from progestin IUDs is low and the contraceptive mechanism is predominantly local. Slynd (drospirenone POP) is oral and would be affected.

What about emergency contraception?

Plan B (levonorgestrel 1.5 mg) and Ella (ulipristal acetate 30 mg) are single-dose oral emergency contraceptives. The tirzepatide interaction study tested chronic combined oral contraceptive use, where peak-level suppression matters most for ovulation suppression. The clinical implication for a single dose of emergency contraception is unclear, but the prudent read is that a copper IUD inserted within 5 days post-coitus is the highest-efficacy emergency option (failure rate <0.1%) and is unaffected by GLP-1 status. For a single-dose oral emergency contraceptive on tirzepatide, prescribers commonly recommend doubling the standard levonorgestrel dose (off-label) or defaulting to ulipristal, though direct interaction data are absent.

Magnitude: pregnancy failure rate per 100 woman-years

The practical protocol

1. If on tirzepatide (Mounjaro, Zepbound) and an oral contraceptive: add a barrier method for 4 weeks starting the day of tirzepatide initiation, and add another 4 weeks of barrier coverage after each dose escalation (2.5 to 5 to 7.5 to 10 to 12.5 to 15 mg). A typical full titration takes 5 months, so the cumulative barrier window is roughly 20 of the first 24 weeks.
2. Better: switch to a non-oral form before starting tirzepatide. A transdermal patch (Xulane), a vaginal ring (NuvaRing or Annovera), a depot injection (Depo-Provera), a subdermal implant (Nexplanon), or an IUD (Mirena, Kyleena, Liletta, Paragard) all bypass the interaction. Plan the switch 4–6 weeks before starting tirzepatide so the alternative method is at steady state.
3. If oral contraception is non-negotiable, consider semaglutide instead. Wegovy and Ozempic have no labelled oral-contraceptive interaction^[3][4]. The total weight-loss magnitude is somewhat lower than tirzepatide in head-to-head and indirect comparisons (STEP-1^[10]: -14.9%; SURMOUNT-1^[9]: -20.9% at 15 mg), but the contraceptive picture is materially simpler.
4. Plan for pregnancy washout separately. Whatever contraceptive you use, all GLP-1 agonists should be discontinued at least 2 months before a planned conception per the labels and current obstetric guidance. See our pregnancy washout article linked below.

Cost and access notes

Under the Affordable Care Act, all FDA-approved contraceptive methods are covered at zero cost-share by most US private insurance plans. Practical out-of-pocket ranges for uninsured or grandfathered plans:

• Oral COCs (generic): $5–15 per month at major retail pharmacies; brands like Loestrin remain higher.
• Transdermal patch (Xulane): roughly $25–50 per month.
• Vaginal ring (NuvaRing): roughly $50–100 per month; generic etonogestrel rings have narrowed the gap.
• Depot injection (Depo-Provera): roughly $50–100 every 12 weeks.
• Implant (Nexplanon): roughly $800–1,300 insertion with 3 years of coverage — the lowest cost per protected year.
• IUD (Mirena, Paragard): roughly $500–1,300 insertion with 5–10 years of coverage — the lowest cost per protected year for any method and unaffected by GLP-1.

Provider routes for non-oral contraception that are compatible with GLP-1 telehealth: Wisp, Hims/Hers, Twentyeight Health, The Pill Club, and Nurx all prescribe transdermal patches and vaginal rings by mail; IUD insertion requires an in-person visit with a primary care, OB-GYN, or Planned Parenthood clinician.

Related research and tools

• Mounjaro and Zepbound birth-control warning — the tirzepatide label deep-dive with verbatim PI quotes
• Ozempic and birth control — why semaglutide does not carry the labelled interaction
• GLP-1 pregnancy 2-month washout — pre-conception discontinuation guidance across the GLP-1 class
• GLP-1, pregnancy, PCOS, and fertility — the broader women's-health picture
• BHRT and GLP-1 in perimenopause — hormone replacement stacking around weight-loss therapy
• Birth control and weight loss — method-specific weight effects independent of GLP-1
• Zepbound (tirzepatide) — full drug profile, dosing ladder, and pricing
• Wegovy (semaglutide) — the semaglutide carve-out option

Important disclaimer. This article is educational and does not constitute medical advice. Contraceptive decisions should be made with a clinician who can review your medical history, smoking status, thromboembolic risk, and personal preference. The tirzepatide oral-contraceptive interaction is documented in the FDA-approved prescribing information and is binding clinical guidance; the 4-week post-initiation and post-escalation barrier windows in this article reflect the label text. FDA label SetIDs were confirmed live in DailyMed on 2026-05-29; PMIDs verified live against the PubMed E-utilities API on 2026-05-29.

Last verified: 2026-05-29. Next review: every 6 months, or sooner if the FDA labels for tirzepatide, semaglutide, or orforglipron are revised, or if a prospective in-vivo interaction study is published.